427PPhase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma.
Saved in:
| Title: | 427PPhase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma. |
|---|---|
| Authors: | Moek, K L1 (AUTHOR), Fiedler, W M2 (AUTHOR), Einem, J C von3 (AUTHOR), Verheul, H M4 (AUTHOR), Seufferlein, T5 (AUTHOR), Groot, D J de1 (AUTHOR), Heinemann, V3 (AUTHOR), Kebenko, M2 (AUTHOR), Oordt, C W Menke-van der Houven van4 (AUTHOR), Ettrich, T J5 (AUTHOR) |
| Source: | Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
